<DOC>
	<DOCNO>NCT01529554</DOCNO>
	<brief_summary>Acute myocardial infarction ( AMI ) constitute major cause death nation death rate morbidity remain substantial year thereafter . Inflammation hallmark throughout distinct stage atherosclerotic lesion formation precede AMI well time plaque rupture post-infarct repair phase . Harnessing harmful consequence constitute attractive therapeutic approach address unmet medical need . The objective study evaluate effect mTOR inhibition ( everolimus ) infarct size , myocardial function inflammation patient ST-Elevation Myocardial Infarction . The efficacy objective : 1 . ( 1° endpoint ) : To assess effect mTOR inhibition ( everolimus ) myocardial infarct size change baseline ( 12-72 hour percutaneous coronary intervention ) 30 day follow-up measure MRI ( Late Gadolinium Enhancement ( LGE ) transmurality ) . 2 . ( 2° endpoint ) : To evaluate microvascular obstruction ( MVO ) change baseline ( 12-72 hour percutaneous coronary intervention ) 30 day follow-up evaluated MRI . 3 . ( 3° endpoint ) : 1 . Change leave ventricular volume baseline ( 12-72 hour percutaneous coronary intervention ) 30 day follow-up measure MRI . 2 . Change biomarkers time coronary angiography 30 day follow-up include time-course ( AUC ) . Biomarkers comprise hs-TnT , NT-proBNP , hs-CRP , IL-6 inflammatory biomarkers OPG , sRANKL , OPN CCN1 . The safety objective : To explore effect mTOR inhibition ( everolimus ) several clinical safety laboratory parameter include plasma lipid level blood count . This complemented analysis inflammatory cell subset coronary thrombi peripheral blood ( CD4+ T helper lymphocyte subset , monocyte subset ) .</brief_summary>
	<brief_title>Controlled Level EVERolimus Acute Coronary Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients enter hospital main diagnosis Acute Coronary Syndrome ( STEMI ) define : 1 . STElevation &gt; 1mm &gt; 2 lead OR Novel leave bundle branch block ( LBBB ) OR Posterior MI STDepression &gt; 1mm &gt; 2 lead 2 . Chest pain duration &gt; 10 minute 3 . Primary Coronary Intervention ( PCI ) drugeluting stent ( DES ) within 24 hour chest pain onset occlude culprit artery 4 . First Myocardial Infarction 5 . Occluded coronary artery angiography 6 . Occlusion coronary vessel proximal third either LAD , RCX RCA , mid segment right coronary artery ( RCA ) mid segment large leave anterior descending ( LAD ) coronary artery , i.e . latter reach apex 7 . Male female patient 18 year 90 year age 8 . Signed informed consent 1 . Participation another drug stent trial 2 . Pregnant woman nurse mother 3 . Mechanical complication acute coronary syndrome 4 . Scheduled PCI additional lesion within 30 day 5 . Major elective surgery plan study period 6 . Malignancy ( unless heal remission &gt; 5 year ) 7 . Chronic infection ( HIV , Tbc , empyema ) 8 . Severely compromised renal function ( GFR &lt; 30 ml/min )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Acute Coronary Syndromes</keyword>
	<keyword>ST-Elevation Myocardial Infarction</keyword>
	<keyword>Infarct size</keyword>
	<keyword>inflammation</keyword>
	<keyword>everolimus</keyword>
</DOC>